文献速递神经肿瘤

立体定向针吸活检取样数量与临床结局的荟萃分析

Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis.
PubMed 文献 · J Neurooncol · 2021-07-12

该荟萃分析纳入PubMed数据库中28个队列、共2416例因肿瘤指征行立体定向针吸活检的患者,按活检取样数分为<3个、3-6个和>6个三组。汇总分析显示,活检相关并发症发生率分别为4.3%、16.3%和17%,组间差异显著(p<0.001);而诊断率(90.4%、93.8%、88.1%)和死亡率在组间无显著差异。结论提示活检并发症风险与取样数量呈非线性关联,取样数量与诊断率或死亡率无关。

要点

  • 取样数<3个的研究并发症汇总估计为4.3%,低于取样3-6个(16.3%)和>6个(17%)的研究。
  • 取样数量与诊断率无关,三组汇总诊断率分别为90.4%、93.8%和88.1%。
  • 取样数量与死亡率无显著差异,并发症风险与取样数呈非线性关联。

核心结论

  • 立体定向针吸活检的并发症风险与取样数量呈非线性关联。
  • 取样数量与诊断率或死亡率之间无关联。

研究设计与样本

  • 荟萃分析与meta回归分析,纳入PubMed数据库研究中28个队列、共2416例因肿瘤指征行立体定向针吸活检的患者。
  • 按活检取样数分为<3个(n=8)、3-6个(n=13)和>6个(n=7)三组研究。

主要发现

  • 活检相关并发症汇总估计:<3个组4.3%,3-6个组16.3%,>6个组17%,组间差异显著(p<0.001)。
  • 诊断率汇总估计:<3个组90.4%,3-6个组93.8%,>6个组88.1%,三组可比。
  • 死亡率在取样数量不同的研究间无显著差异。

关键数值与推荐

  • 并发症汇总估计分别为4.3%(<3个)、16.3%(3-6个)、17%(>6个),组间p<0.001。
  • 诊断率汇总估计分别为90.4%(<3个)、93.8%(3-6个)、88.1%(>6个)。

临床怎么用

  • 对于位置难以开放手术到达的脑肿瘤,立体定向针吸活检仍是组织诊断的基石。
  • 取样数量增加并不提高诊断率,临床决策时应权衡取样数量与并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic needle biopsy remains the cornerstone for tissue diagnosis for tumors located in regions of the brain that are difficult to access through open surgery. OBJECTIVE: We perform a meta-analysis of the literature to examine the relation between number of samples taken during biopsy and diagnostic yield, morbidity and mortality. METHODS: We identified 2416 patients from 28 cohorts in studies published in PubMed database that studied stereotactic needle biopsies for tumor indications. Meta-analysis by proportions and meta-regression analyses were performed. RESULTS: On meta-analysis, the morbidity profile of the published needle biopsy studies clustered into three groups: studies that performed < 3 samples (n = 8), 3-6 samples (n = 13), and > 6 samples during biopsy (n = 7). Pooled estimates for biopsy related morbidity were 4.3%, 16.3%, and 17% for studies reporting < 3, 3-6, and > 6 biopsy samples, respectively. While these morbidity estimates significantly differed (p < 0.001), the diagnostic yields reported for studies performing < 3 biopsies, 3-6 samples, and > 6 samples were comparable. Pooled estimates of diagnostic yield for these three groups were 90.4%, 93.8%, and 88.1%, respectively. Mortality did not significantly differ between studies reporting differing number of samples taken during biopsy. CONCLUSIONS: Our meta-analysis suggests that morbidity risk in needle biopsy is non-linearly associated with the number of samples taken. There was no association between the number of biopsies taken, and diagnostic yield or mortality.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dhawan S, Venteicher AS, Butler WE, et al. Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis. J Neurooncol. 2021. PMID: 34251602. doi:10.1007/s11060-021-03785-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。